BACKGROUND: Between 10 and 15% of patients admitted for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) show no obstructive coronary artery disease (NO-CAD) at angiography. Coronary microvascular spasm is a possible mechanism of the syndrome, but there are scarce data about coronary microvascular function in these patients. OBJECTIVES: To assess coronary microvascular function in patients with NSTE-ACS and NO-CAD. METHODS: We studied 30 patients (67 ± 10 years, 19 female) with NSTE-ACS and NO-CAD. Specific causes of NSTE-ACS presentation (e.g., variant angina, takotsubo disease, tachyarrhythmias, etc.) were excluded. Coronary blood flow (CBF) velocity response to IV ergonovine (6 µg/kg up to a maximal dose of 400 µg) was evaluated before discharge by transthoracic Doppler echocardiography. CBF response to IV adenosine (140 μg/kg/min) and cold pressor test (CPT) was also assessed after 1 month. Ten age- and sex-matched patients with non-cardiac chest pain served as controls. Vasoactive tests were repeated after 12 months in 10 NSTE-ACS patients. RESULTS: The ergonovine/basal CBF velocity ratio was 0.79 ± 0.09 and 0.99 ± 0.01 in patients and controls, respectively (p < 0.001). The adenosine/basal CBF velocity ratio was 1.46 ± 0.2 and 3.25 ± 1.2 in patients and controls, respectively (p < 0.001), and the CPT/basal CBF velocity ratio was 1.36 ± 0.2 and 2.43 ± 0.3 in the 2 groups, respectively (p < 0.001). In 10 patients assessed after 12 months, CBF velocity responses to ergonovine, adenosine, and CPT were found to be unchanged. CONCLUSIONS: Patients with NSTE-ACS and NO-CAD exhibit a significant coronary dysfunction, which seems to involve both an increased constrictor reactivity, likely mainly involving coronary microcirculation, and a reduced microvascular dilator function, both persisting at 12-month follow-up.
BACKGROUND: Between 10 and 15% of patients admitted for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) show no obstructive coronary artery disease (NO-CAD) at angiography. Coronary microvascular spasm is a possible mechanism of the syndrome, but there are scarce data about coronary microvascular function in these patients. OBJECTIVES: To assess coronary microvascular function in patients with NSTE-ACS and NO-CAD. METHODS: We studied 30 patients (67 ± 10 years, 19 female) with NSTE-ACS and NO-CAD. Specific causes of NSTE-ACS presentation (e.g., variant angina, takotsubo disease, tachyarrhythmias, etc.) were excluded. Coronary blood flow (CBF) velocity response to IV ergonovine (6 µg/kg up to a maximal dose of 400 µg) was evaluated before discharge by transthoracic Doppler echocardiography. CBF response to IV adenosine (140 μg/kg/min) and cold pressor test (CPT) was also assessed after 1 month. Ten age- and sex-matched patients with non-cardiac chest pain served as controls. Vasoactive tests were repeated after 12 months in 10 NSTE-ACS patients. RESULTS: The ergonovine/basal CBF velocity ratio was 0.79 ± 0.09 and 0.99 ± 0.01 in patients and controls, respectively (p < 0.001). The adenosine/basal CBF velocity ratio was 1.46 ± 0.2 and 3.25 ± 1.2 in patients and controls, respectively (p < 0.001), and the CPT/basal CBF velocity ratio was 1.36 ± 0.2 and 2.43 ± 0.3 in the 2 groups, respectively (p < 0.001). In 10 patients assessed after 12 months, CBF velocity responses to ergonovine, adenosine, and CPT were found to be unchanged. CONCLUSIONS:Patients with NSTE-ACS and NO-CAD exhibit a significant coronary dysfunction, which seems to involve both an increased constrictor reactivity, likely mainly involving coronary microcirculation, and a reduced microvascular dilator function, both persisting at 12-month follow-up.
Entities:
Keywords:
Acute coronary syndrome with no obstructive coronary artery disease; Coronary microvascular dysfunction; Microvascular spasm
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Bernard R Chaitman; Jeroen J Bax; David A Morrow; Harvey D White Journal: Circulation Date: 2018-11-13 Impact factor: 29.690
Authors: J S Hochman; J E Tamis; T D Thompson; W D Weaver; H D White; F Van de Werf; P Aylward; E J Topol; R M Califf Journal: N Engl J Med Date: 1999-07-22 Impact factor: 91.245
Authors: Erika R Gehrie; Harmony R Reynolds; Anita Y Chen; Brian H Neelon; Matthew T Roe; W Brian Gibler; E Magnus Ohman; L Kristin Newby; Eric D Peterson; Judith S Hochman Journal: Am Heart J Date: 2009-10 Impact factor: 4.749
Authors: John F Beltrame; Filippo Crea; Juan Carlos Kaski; Hisao Ogawa; Peter Ong; Udo Sechtem; Hiroaki Shimokawa; C Noel Bairey Merz Journal: Eur Heart J Date: 2017-09-01 Impact factor: 29.983
Authors: Rocco Antonio Montone; Giampaolo Niccoli; Michele Russo; Marta Giaccari; Marco Giuseppe Del Buono; Maria Chiara Meucci; Filippo Gurguglione; Rocco Vergallo; Domenico D'Amario; Antonino Buffon; Antonio M Leone; Francesco Burzotta; Cristina Aurigemma; Carlo Trani; Giovanna Liuzzo; Gaetano A Lanza; Filippo Crea Journal: Clin Res Cardiol Date: 2019-07-03 Impact factor: 5.460
Authors: Barbara Kutryb-Zajac; Patrycja Jablonska; Marcin Serocki; Alicja Bulinska; Paulina Mierzejewska; Daniela Friebe; Christina Alter; Agnieszka Jasztal; Romuald Lango; Jan Rogowski; Rafal Bartoszewski; Ewa M Slominska; Stefan Chlopicki; Jürgen Schrader; Magdi H Yacoub; Ryszard T Smolenski Journal: Clin Res Cardiol Date: 2019-05-29 Impact factor: 5.460
Authors: Niya Mileva; Sakura Nagumo; Takuya Mizukami; Jeroen Sonck; Colin Berry; Emanuele Gallinoro; Giovanni Monizzi; Alessandro Candreva; Daniel Munhoz; Dobrin Vassilev; Martin Penicka; Emanuele Barbato; Bernard De Bruyne; Carlos Collet Journal: J Am Heart Assoc Date: 2022-03-18 Impact factor: 6.106